due an update, page-6

Just read their latest announcement. China problem continues and won't be resolved quickly. Money is obviously a big problem now. I note their voluntary pay cuts though they aren't the first biotech to do this. They've put in a few estimations of time for resolution of various things but I'm guessing you could double those. Not relisting any time soon and i would think they are in big trouble. Yes I also have no idea where they are going to financing a long and expensive thromboview trial. To me it looks very bleak.